Table 1.
Patient characteristics.
| Age, years | 54.4 ± 14.8 |
| Male sex | 26/39 (66.7%) |
| Underlying cardiomyopathy prior to transplant | Ischaemic cardiomyopathy: 11/39 (28.2%) |
| Dilated cardiomyopathy: 18/39 (46.2%) | |
| Hypertrophic cardiomyopathy: 4/39 (10.2%) | |
| Valvular cardiomyopathy: 3/39 (7.7%) | |
| Other: 3/39 (7.7%) | |
| Blood type | O: 15/39 (38.5%) |
| A: 15/39 (38.5%) | |
| B: 8/39 (20.5%) | |
| AB: 1/39 (2.5%) | |
| Time from transplantation, years | 4.9 (1.8–7.7) |
| Prior acute rejection | 25/39 (64.1%) |
| ISHLT cardiac allograft vasculopathy 2 or 3 | 9/39 (23.1%) |
| Serology status | |
| CMV‐positive | 26/38 (68.4%) |
| EBV‐positive | 35/37 (94.6%) |
| Baseline echocardiographic evaluation | |
| LV ejection fraction, % | 64.0 (60.0–68.0) |
| LV end‐diastolic diameter, mm | 48.0 (44–51.0) |
| Kidney function | |
| Creatinine, µmol/l | 126 (98.0–163.5) |
| Chronic kidney disease stage III or higher | 21/39 (53.8%) |
| On dialysis | 6/39 (15.4%) |
| Prior cardiac arrhythmia | 4/39 (10.3%) |
| Inflammatory disease | 5/39 (12.8%) |
| Prior stroke or transient ischaemic attack | 6/39 (15.4%) |
| Peripheral vascular disease | 2/39 (5.1%) |
| Active smoking | 2/39 (5.1%) |
| Diabetes mellitus | 16/39 (40.0%) |
| Dyslipidaemia | 12/39 (30.8%) |
| Hypertension | 28/39 (71.8%) |
| Family history of cardiovascular disease | 4/39 (10.3%) |
| Body mass index, kg/m2 | 27.0 ± 5.5 |
| Baseline medication | |
| Single antiplatelet therapy | 30/39 (76.9.5%) |
| Dual antiplatelet therapy | 5/39 (12.8%) |
| Statin | 30/39 (76.9%) |
| Beta‐blocker | 26/39 (66.7%) |
| ACE‐I or ARBs | 16/39 (41.0%) |
| MRA | 1/39 (2.6%) |
| Oral anticoagulant | 3/39 (7.7%) |
| Insulin | 10/39 (25.6%) |
| Oral antidiabetic agent | 3/39 (7.7%) |
| Prednisone | 37/39 (94.9%) |
| Prednisone dosage >10 mg per day | 7/37 (18.9%) |
| Mycophenolate mofetil | 28/39 (71.8%) |
| Tacrolimus | 16/39 (41.0%) |
| Cyclosporine | 22/39 (56.4%) |
| Everolimus | 11/39 (28.2%) |
| Azathioprine | 4/39 (10.3%) |
ACE‐I, angiotensin‐converting enzyme inhibitors; ARB: angiotensin receptor blockers; CMV, cytomegalovirus; EBV, Epstein Barr virus; LV, left ventricular; ISHLT: International Society for Heart and Lung Transplantation; MRA: mineralocorticoid receptor antagonist.
Variables are provided as mean ± standard deviation or median (IQR).